NewsSignals AI analysis·Benzinga·Oct 23, 2026

SystImmune, Bristol Myers: iza-bren cuts HR+/HER2- breast cancer risk 59% vs chemo

Grade Abullish AI signal$BMYSTOCK

SystImmune and Bristol Myers Squibb reported late-breaking oral ESMO 2026 results showing that iza-bren reduced risk by 59% versus chemotherapy in HR+/HER2- breast cancer. The companies said two positive Phase 3 breast cancer trials reinforce iza-bren's potential to redefine treatment. The results provide a new clinical catalyst for Bristol Myers Squibb and the breast cancer treatment sector.

Bullish strength: 51/100

BMY partner drug significantly improves progression-free survival in Phase III
Risk reduced by 59%, with a significant increase in objective response rate

Bearish strength: 49/100

The link between BMYSTOCK and BMY drug news is unclear
Overall survival data are not yet mature

This is automated NewsSignals analysis of third-party reporting, not independent original reporting or investment advice. AI scores are not price predictions.

Read the original source ↗

← Browse more news analysis

Trade on MEXC

More recent source-attributed AI analysis.

US Fintech Weekly: Fiserv Bounces Post-Earnings, Crypto Brokers Suffer, And Federal Agencies Prepare Innovation Guidelines

Fiserv shares surged nearly 13% after earnings, while crypto-linked stocks Robinhood and Coinbase headed for a sixth consecutive weekly decline amid Bitcoin weakness and growing regulatory uncertainty. Fiserv benefited from an earnings beat and a new $500 million share buyback authorization, while six federal agencies are preparing fintech innovation guidelines ahead of a November 15 deadline. Stronger regulatory oversight under Democratic congressional control could pressure crypto platforms, although continued institutional integration may limit the sector's downside.

Corn, soybean futures sag under weight of big US crops

US corn and soybean futures fell to multi-month lows as large domestic harvests continued to weigh on prices, with corn approaching a four-month low and soybeans hitting a 2-1/2-month low. December corn closed down 4.25 cents at $4.40 per bushel, while January soybeans dropped 14 cents to $11.88¼; analysts expect the USDA to report a record-large soybean harvest next week. Rising US crop supplies could maintain downward pressure on corn and soybean prices, while wheat may remain sensitive to developments surrounding Black Sea shipping access.

Healthcare, Insurers 'Best Places to Hide' on AI Cycle Unwind Worries — Market Talk

UBS identifies Australian healthcare and insurance stocks as potential defensive havens if concerns about an unwinding AI trade intensify. The sectors have shown negative share-price correlations with the PHLX Semiconductor Index and Global DC Index, while UBS maintains overweight recommendations on both. Their relative independence from the AI cycle could provide portfolio protection if technology stocks face further pressure.

Gold climbs to two-week high as dollar, yields weaken

Gold climbed 1% to $4,102.50 per ounce, reaching its highest settlement since October 21 as a weaker US dollar and falling Treasury yields boosted demand. The 10-year Treasury yield dropped 5.5 basis points to 4.836%, while silver gained 0.2% to $52.233 per ounce. Gold could face renewed selling pressure if Friday's US jobs report strengthens expectations for a December Fed rate hike, despite improving near-term momentum.